A recent analysis of clinical trials data for metastatic kidney cancer at the Dana Farber Cancer Institute found that taking a common type of high blood pressure medication—angiotensin-system-blockers (ASIs) —may prolong life. Advanced kidney cancer patients with hypertension who took ASI’s (including ACE-inhibitors) during treatment lived an average of seven months longer than those who did not take the drugs. Half of the patients in the clinical study had baseline hypertension prior to starting cancer therapy. In addition, hypertension can be a common side effect of antiangiogenic drugs used in treating kidney cancer.
In previous scientific studies, ASIs have been found to have antiangiogenic properties. The study\’s investigators hypothesize that ASIs may act in synergy with anti-VEGF agents to inhibit angiogenesis, slow tumor growth and restrain metastasis.
In the recent clinical analyses which was presented at the ASCO 2014 Genitourinary Cancers Symposium, the greatest survival benefits were seen in patients who took ASIs while being treated with drugs that target the vascular endothelial growth factor (VEGF) pathway, such as sunitinib, soarfenib, and axitinib. These findings are based on a retrospective study using a database of phase 2 and phase 3 clinical trial results for 4,736 patients treated between 2003 and 2013 for metastatic kidney cancer.
Source: ASCO 2014 GU Symposium